Merck said Thursday it has won FDA approval for Lipfendra, a daily pill that offers patients a new way to fight dangerous cholesterol levels when statins fall short. The drug represents a shift in how millions of Americans might manage their cardiovascular health.
Statins have dominated cholesterol treatment for decades as the most prescribed medication in the US. But they come with a persistent problem: roughly 70 percent of patients never reach their target LDL, or bad cholesterol, levels. Some patients also experience muscle aches, limiting their willingness to take the drugs consistently.
Lipfendra belongs to a class called PCSK9 inhibitors. Unlike earlier versions that required injections, this new formulation comes as a pill, a change that could dramatically expand its use. Dr. Paja Banka, Merck's associate vice-president for global clinical development and a pediatric cardiologist, framed the approval as a breakthrough for patients whose cholesterol remains stubbornly high despite existing therapies.
The drug can work alongside statins or serve as a standalone option. In clinical trials, side effects proved minimal, with none of the muscle pain that plagues statin users. Trial data showed the medication performed essentially like a placebo in terms of adverse effects.
Clinical testing demonstrated that Lipfendra can drive LDL levels down to 50 or 60 or even lower, well below recommended targets. Current medical guidelines from the American College of Cardiology and American Heart Association, issued this spring, call for LDL levels below 100 for most patients, with stricter targets of 70 or lower for high-risk individuals. For patients with existing cardiovascular disease, the goal drops to below 55.
Heart disease kills more Americans than any other cause. LDL buildup in artery walls triggers atherosclerotic disease, which accounts for thousands of heart attacks and strokes each year. A more effective, easier-to-use treatment could shift outcomes significantly across the population.
Merck expects the pill to reach pharmacies within weeks. The company set the list price at $10.50 daily, translating to roughly $300 monthly, though officials say out-of-pocket costs for many insured patients should run substantially lower once coverage kicks in.
Author James Rodriguez: "A pill version of a powerful cholesterol fighter could finally get millions of patients to their targets, but price and insurance coverage will determine whether this actually changes practice."
Comments